The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Thanks Bignose, as we all know Fortacin is a world class product and there is a fairdinkum need out there so overcoming the product supply issues is a major step forward. Heimdal
VXR re-branded as DEVELOP during a powerful presentation by Bill Beament at Diggers and Dealers Mining Forum today, with a new website already up and running: https://develop.com.au . Watching the D&D live feed BB came across like some sort of Elon Musk of the mining sector with his grand vision, runs on the board and unconventional with the shirt hanging out.
DEVELOP now expanding into project funding, mine planning and development. This approach should provide lots of blue sky.
Re-branding preso ( https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02402749-6A1044138?access_token=83ff96335c2d45a094df02a206a39ff4 ) provided just as ASX was closing so it will be interesting to see how the market reacts tomorrow / later this week.
Heimdal
VXR trading @ 84.5c this morning! Our holding is currently valued at c. HK$ 140,400,000 = 39% of the MCap of ERPG
VXR just commenced a significant $10m drilling campaign at Sulphur Springs, WA, to further de-risk the copper project, expand the resource base, and speed up final funding. Corporate update (including re-branding) to follow next week.
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02400379-6A1042940?access_token=83ff96335c2d45a094df02a206a39ff4 .
Should go down well with Aussie punters.
Heimdal
http://www.aastocks.com/tc/stocks/news/aafn-news/NOW.1115892/2
News out in China: http://finance.eastmoney.com/a/202107282019393516.html
Strongly agree Italian.
Very encouraging indeed Bignose :-)
Thanks Italian, a very interesting development indeed. Smart move to use the 5,000 COVID-positive patients
from 11 different hospitals in New York. Seems like the DLI team is on fire and hopefully they will hit jackpot sooner or later.
I like the current set up with 1) the developing VXR Cu story, 2) DLI and 3) Fortacin - no longer a boring one pony show. Heimdal
I think the average VXR purchase price (back in the day) was about AU$1.35/share, as such Jamie might look at a block trade exit at that level which should give us AU$39,000,000 or HK$223,300,000. With Cu production in WA edging ever closer coupled with a full blown Cu rally might catapult us to that goal sooner than we think. It could also be a cut and run at say AU$1/share, who knows. Once we offload our sizable VXR holding the market will take notice.
Hang Seng in complete melt down mode. Down another 1,000 points at the moment, with the Hang Seng Index down 8% in just two days. Unbelievable!
VXR up 8.7% today on the highest volume in weeks. Our holding is now valued at HK$122,700,000 or 34.1% of the ERPG MCap.
If Jamie converted our 1,694,913 new VXR options @ AU$0.135 our holding would be HK$130,300,000 or 36.2% of the MCap.
Heimdal
Hang Seng down 4.13% / 1,130 points today! Index back to early Nov 2020 level. Must be one of the worst performing exchanges in the world this year. VXR doing well as Cu prices bouncing back and a new Director appointed today. Heimdal
Thanks for the heads-up Bothwell, sounds very promising indeed :-) Heimdal
Thanks Bothwell, sounds like a promising extract from a company e.mail. I like the bit part about "licensing partners have access to data room". As Bignose noted "Now that the marketing report is finished, there is now something with a lot more substance and of value to bring to the table and since this data will only have a finite timeline, a license agreement could well be in place long before the phase III finishes, although I am beginning to feel it may not now be as lucrative to us shareholders as we have been led to believe." I agree with Bignose and other posters that Fortacin will most likely not be a blockbuster, nonetheless, in light of the current ultra low MCap we should do fairly well once we secure a US license agreement. The combined income from China, EU, Taiwan, HK, Macao, USA and ROW will all add up and with a conservative P/E of 10-15 we must be looking at a multi-bagger from these shocking low levels. Heimdal
Very disappointing indeed. Sold down on low volume. Difficult to make any headway in this market.
Hang Seng Index back to JAN 1 level. VXR holding up well. ERPG MCAp just 37m pound now!
Sooner or later we must bounce from these crazy levels. A fair bit of news to look forward to for the rest
of this year: FDA Phase II submission AUG -> FDA green light, Start Phase III, Start clinical trials in China in OCT,
EU news, Taiwan, ?Japan, ?ROW, further developments on the DLI / longevity front, VXR exit? Given the news flow
coupled with the very low MCap we should hold up fairly well - limited downside. Heimdal
Fantastic news! Formal registration of the Phase II validation study of Fortacin is a critical and positive step forward; de-risking our world class product in USA. Heimdal
Comedy at its finest Bignose :-) "I said stay at the door!" lol.
Interesting development with the Chinese companies listed in the States. A record $12.5 billion has been raised so far in 2021 in 34 offerings from listings of Chinese firms in the U.S., well up from the $1.9 billion worth of new listings in 14 deals during 2020. Sounds like the mainland Chinese are pushing for Shanghai listings rather than US and HK. First the failed Ant Group IPO in HK and now the Didi debacle. Maybe Jim should consider a dual listing for PRPG in London or NY and longer term move completely out of HK if the geopolitical situation deteriorates further. Heimdal
I agree with Dougie. This is a very tough market and VXR and 575 are holding up very well considering the strong headwinds.
https://www.bloomberg.com/news/articles/2021-07-07/down-831-billion-china-tech-firm-selloff-may-be-far-from-over
Hang Seng out of sync with main western markets with all 2021 gains now wiped and back to JAN 1 start level.
Crypto, gold and copper all under pressure. Mountain Valley MD (as promoted by Charlie) is down from $2.29 in FEB and now trading at just 29c, AMC now back at $49, retreating 47% from the June high and looking quite soft.
While I share the frustration of Bignose, I think Dougie is correct - a good FDA outcome can certainly not be ruled out. The Italian is in contact with the company and the recent STAY TUNED message was reassuring. Hopefully a solid Market Update next week. (Maybe) a positive profit alert next month and Chinese clinical trials only 3 months away now. Heimdal